S-Adenosylmethionine And Methylthioadensosine In Chemoprevention And Treatment Of Colon Polyps And Cancer
AssigneeUniversity of Southern California
InventorShelly C. Lu
Life of this patent
Estimating the term…
Abstract
The present invention relates to S-adenosylmethionine (SAMe), methylthioadenosine (MTA) for the treatment of disease. More specifically, the invention relates to SAMe and MTA methods and compositions for the chemoprevention and treatment of colon polyps and cancer.
Claims38
1-18. (canceled)
A pharmaceutical composition for use in treating cancer, comprising:
- at least one of SAMe or MTA;
- and
- a pharmaceutically suitable carrier.
A pharmaceutical composition for use in chemoprevention of cancer, comprising:
- at least one of SAMe or MTA;
- and
- a pharmaceutically suitable carrier.
A composition for use in inducing apoptosis in cancerous cells, comprising:
- at least one of SAMe or MTA.
A pharmaceutical composition for use as an adjunct to a chemotherapeutic agent, comprising:
- at least one of SAMe or MTA;
- and
- a pharmaceutically suitable carrier.
A composition for use in blocking the expression of MAT2A and/or c-FLIP in cells, comprising:
- at least one of SAMe or MTA.
A method of treating cancer in a subject, comprising the step of:
- administering to the subject a pharmaceutical composition at a predetermined dosage and duration,
- wherein said composition comprises at least one of SAMe or MTA.
The method of 35, wherein said composition further comprising a chemotherapeutic agent.
A chemoprevention method for an epithelial cancer, comprising:
- administering a pharmaceutical composition to a subject at a predetermined dosage and duration,
- wherein said pharmaceutical composition comprises at least one of SAMe or MTA.
A method for selectively inducing apoptosis in a population of epithelial cells, comprising:
- contacting said population of epithelial cells with at least one of SAMe or MTA at a concentration of about 0.5 mM or higher for a duration of 16 hours or more,
- wherein said population of epithelial cells contain at least one cancerous cell, and whereby contacting said population of cells with SAMe or MTA or both results selective induction of apoptosis in the cancerous cell.
A method of diagnosing cancer in a subject, comprising:
- detecting expression of MAT2A and MAT2β in a sample of epithelial cells obtained from a subject;
- and
- comparing the expression level of MAT2A and MAT2β in the sample to a normal reference,
- whereupon if the expression level of MAT2A and MAT2β in the sample is higher than the normal reference, a diagnosis of cancer is indicated.
A method of cancer diagnosis, comprising the steps of:
- detecting expression of MAT in a sample of epithelial cells obtained from a subject;
- and
- comparing the expression level in the sample to a normal reference,
- wherein if an abnormal level of MAT expression is detected in the sample, a cancer diagnosis is indicated.
A systematic method of developing a pharmaceutical composition for use in treating cancer, comprising:
- selecting an apoptosis-inducing agent known to have cancer cells resistant to it;
- and
- applying said apoptosis-inducing chemotherapeutic agent and at least one of SAMe or MTA to said resistant cancer cells;
- whereby a pharmaceutical composition is developed if the combination is more effective in inducing apoptosis in the cancer cells than the chemotherapeutic agent alone.
Dependencies are inferred from the claim text.